Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy and is highly resistant to standard treatment regimens. Targeted therapies against KRAS, a mutation present in an overwhelming majority of PDAC cases, have been largely ineffective. However, inhibition of downstream components in the KRAS signaling cascade provides promising therapeutic targets in the management of PDAC and warrants further exploration. Here, we investigated Urolithin A (Uro A), a novel natural compound derived from pomegranates, which targets numerous kinases downstream of KRAS, in particular the PI3K/AKT/mTOR signaling pathways. We showed that treatment of PDAC cells with Uro A blocked the phosphorylation of AKT and p70S6K in vitro, successfully inhibited the growth of tumor xenografts, and increased overall survival of Ptf1aCre/+;LSL-KrasG12D/+;Tgfbr2flox/flox (PKT) mice compared with vehicle or gemcitabine therapy alone. Histologic evaluation of these Uro A–treated tumor samples confirmed mechanistic actions of Uro A via decreased phosphorylation of AKT and p70S6K, reduced proliferation, and increased cellular apoptosis in both xenograft and PKT mouse models. In addition, Uro A treatment reprogrammed the tumor microenvironment, as evidenced by reduced levels of infiltrating immunosuppressive cell populations such as myeloid-derived suppressor cells, tumor-associated macrophages, and regulatory T cells. Overall, this work provides convincing preclinical evidence for the utility of Uro A as a therapeutic agent in PDAC through suppression of the PI3K/AKT/mTOR pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Natural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858 · cited 2×
“In fact, a growing number of FDA-approved anticancer agents are derived from either naturally occurring compounds or their derivatives (5, 6).”
BackgroundmTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 1×
“AKT activity is dependent on phosphorylation at two sites: T308, which is activated by phosphoinositide-dependent kinase-1 (PDK1), and S473, which is activated by PI3K and mTORC2 complex composed of mTOR, rictor, and Sin1 (25, 26).”
BackgroundM-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287 · cited 1×
“Tregs are critically dependent on the transcription factor FoxP3 (29), and TAMs are primarily identified as the F4/80þ population (30).”
BackgroundmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · cited 2×
“AKT and p70S6K enhances proliferation, inhibits apoptosis, and promotes invasion and metastasis in PDAC (24).”
BackgroundRyan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 3×
“The PI3K signaling pathway is a downstream effector of oncogenic KRAS (35), which is nearly ubiquitous in PDAC.”
BackgroundBayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947
Cited by
Impact of the natural compound urolithin a on health, disease, and aging
D’Amico, D., Andreux, P. A., Valdés, P., Singh, A., Rinsch, C., & Auwerx, J. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.04.009 · Cited by 419
A Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy
Yang, Q., Wang, B., Zheng, Q., Li, H., Meng, X., Zhou, F., & Zhang, L. (2023) · Advanced Science · doi:10.1002/advs.202207366 · Cited by 240
Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress
Mehra, S., Deshpande, N., & Nagathihalli, N. (2021) · Cancers · doi:10.3390/cancers13174434 · Cited by 85
“Previously, we have d monstrated that Urolithin A mediated simultaneous targeting of the PI3K/Akt/mTOR pathway reduced PDAC tumor growth and improved survi al in the genetically e gineered mouse model (GEMM) of PDAC [15].”
BackgroundInfluentialSelf-citationBeygi, M., Oroojalian, F., Hosseini, S. S., Mokhtarzadeh, A., Kesharwani, P., & Sahebkar, A. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101209 · Cited by 32
RetractedHusain, K., Villalobos-Ayala, K., Laverde, V., Vazquez, O. A., Miller, B., Kazim, S., Blanck, G., Hibbs, M. L., Krystal, G., Elhussin, I., et al. (2022) · Cancers · doi:10.3390/cancers14153613 · Cited by 26
“The inhibition of PC cell growth by API may be due to the downregulation of PI3K/AKT and MAPK/MEK/ERK pathways as these kinases are down stream of Kras oncogene which is mutated in 90% of patients with PC [79,80].”
Background
Metadata
- Authors
- Totiger, T. M., Srinivasan, S., Jala, V. R., Lamichhane, P., Dosch, A. R., Gaidarski, A. A., Joshi, C., Rangappa, S., Castellanos, J., Vemula, P. K., Chen, X., Kwon, D., Kashikar, N., VanSaun, M., Merchant, N. B., & Nagathihalli, N. S.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2019-02-01
- Volume
- 18
- Issue
- 2
- Pages
- 301-311
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2900126416
- Cited by
- 121
- References
- 16
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/1535-7163.mct-18-0464
- The paper
- Totiger, T. M., Srinivasan, S., Jala, V. R., Lamichhane, P., Dosch, A. R., Gaidarski, A. A., Joshi, C., Rangappa, S., Castellanos, J., Vemula, P. K., Chen, X., Kwon, D., Kashikar, N., VanSaun, M., Merchant, N. B., & Nagathihalli, N. S. (2019). Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-18-0464
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.